Dr. Alyssa Small Layne digs into why Bloomberg’s “IVF Disrupted” resonated so widely and what it reveals about the modern fertility industry. She explains how a specialty that once covered broad reproductive care narrowed to one core product—IVF—then absorbed private-equity incentives and startup-style operations. The result can be speed over safeguards, glossy lobbies over lab quality, and patients left guessing about real risk.
In this episode, you’ll learn how to look past marketing, ask process-focused questions, and spot profit-driven decisions before they shape your care. Press play to learn how to evaluate clinics with clarity and confidence.
What You’ll Learn:
03:14 — How REI shifted from medicine to marketing
04:50 — Why private equity targets IVF clinics
06:52 — How fast growth leads to dangerous mistakes
08:20 — Real cases of embryo mix-ups and clinic errors
14:30 — The lab procedures you never get to see
16:50 — Why clinics reject patients to protect success rates
17:34 — Add-on procedures that increase cost but not outcomes
19:39 — How intended parents can push for industry change
Resources Mentioned:
SMS#47 Hidden Risks of PGT-A Testing in IVF and Surrogacy - Allison Freeman
Key Takeaways:
A narrow, procedure-driven model can sideline safety and transparency.
Lobby aesthetics never substitute for validated lab processes and controls.
Profit incentives may shape add-ons, timelines, and who performs procedures.
Ask precise, process-focused questions to evaluate real clinic safeguards.
Choosing or re-evaluating a clinic? Use today’s questions to assess lab quality, staffing, and add-on recommendations—then press play for the full guide.
“Don’t judge care by the lobby. Ask how the lab protects your embryos.”
